摘要
目的探讨厄罗替尼治疗非小细胞肺癌(NSCLC)的疗效。方法 42例NSCLC患者每天口服厄罗替尼150mg行靶向治疗,直至疾病进展或出现不可耐受的不良反应。对其中的12例检测了表皮生长因子受体(EGFR)基因突变。采用RECIST实体瘤疗效评价标准评价疗效,NCI毒性评价标准评价不良反应。结果 42例患者中,疾病部分缓解(PR)18例,疾病稳定(SD)16例,疾病进展(PD)8例;客观有效率(ORR)为42.8%,疾病控制率(DCR)为80.9%。12例接受基因突变检测结果:突变型9例,野生型3例;中位无疾病进展生存期(PFS)分别为9个月(95%CI为6-13个月)和15d(95%CI为15-30d)(P<0.01);中位总生存期(OS)分别为11个月(95%CI为6-14个月)和2个月(95%CI为1-5个月)(P<0.01)。42例患者中,最常见的不良反应是皮疹(73.8%)和腹泻(28.5%)。结论厄罗替尼对于NSCLC患者有效,尤其对于EGFR基因突变者疗效确切,不良反应小。
Objective To evaluate the efficacy of erlotinib in the treatment of advanced non- small cell lung cancer（NSCLC）. Methods A total of 42 patients with advanced NSCLC was treated with oral erlotinib 150 mg once daily until the disease was progressed or toxicity intolerated. The epidermal growth factor receptor（EGFR） gene mutation was examined in 12 of 42 cases. The efficacy was evaluated with RECIST criteria and the adverse events were evaluated according to NCI criteria. Results The objective response rate was 42. 8% and disease control rate was 80. 9% in 42 patients, with partical remission in 18 cases, stable disease in 16 cases and progressed disease in 8 cases. EGFR mutation analysis showed gene mutations in 9 cases and wild type in 3 cases. The median progression- free survival times in the patients with and without EGFR gene mutations were 9 months and 15 days, respectively（P〈0.01） and the median overall survival times were 11 months and 2 months, respectively（P〈0. 01 ）. The main adverse events were skin rash （73.8%） and diarrhea （28. 5 %）. Conclusion Erlotinib is effective and safe for the treatment of advanced NSCLC, especially for those with EGFR gene mutation.
出处
《江苏医药》
CAS
北大核心
2013年第8期935-938,共4页
Jiangsu Medical Journal
关键词
厄罗替尼
非小细胞肺癌
靶向治疗
Erlotinib
Non-small cell lung cancer, Targeted therapy
